At the 2022 ABA Health Law Section Emerging Issues in Health Law Conference in Miami, Florida, our founder, Jason Ruchaber, CFA, ASA, and Allison Emhardt, Associate General Counsel IU Health, discuss the perfect storm created by COVID-19, the 2021 Medicare Physician Fee Schedule, and changes in the Stark Law and Antikickback Statute.  Together these changes make structuring compliant physician compensation arrangements and assessing fair market value more difficult than ever. In this presentation the panelist discuss these changes and provide guidance around best practices for structuring physician compensation models in 2022 and beyond.


Jason Ruchaber, CFA, ASA, founder and managing partner of Root Valuation, and Clay Countryman, partner of Breazeale Sachse & Wilson, discuss recent changes in the Stark Law and Antikickback Statute impacting FMV



McGuire Woods 13th Annual Healthcare Finance and Growth Conference

Eye Care Investments have been a very attractive niche for healthcare investors with more than 20 private equity placements in 2016 and 2017, and numerous other deals announced or pending during 2018. This investment activity is spurred on by very attractive fundamentals and a highly fragmented market ripe for consolidation. Paired with an ever-increasing regulatory and technological burden, many independent optometrists and ophthalmologists see strategic alignment as a means to refocus their efforts on patient care while gaining the economic benefit of a partial liquidity event.

With the heightened investment activity and media coverage of these deals, it can be difficult to distill fact from fiction. To help shed light on the economic and other variables driving eye care investments, I am very pleased to be participating on the Eye Care Investments panel at McGuire Woods 13th Annual Healthcare Finance and Growth Conference next Tuesday, September 25th. Together with my co-panelists Jose Costa, CEO of For Eyes by GrandVision, and Steven Boyd, Managing Director with Alvarez & Marsal, we will be discussing eye care investments from three distinct perspectives, including:

  • Current Transactional Trends

  • Characteristics of Attractive Investment Opportunities

  • Key Value Drivers and FMV Considerations

  • Eye Care Industry Innovation and Disruption

If you have not already registered for this excellent conference, you can do so by clicking on the following link. If you are unable to attend and would like to learn more about eye care investments, I will be posting a summary of our discussion to my blog following the conference. Hope to see you there!

The Myth of the Healthcare Multiple

BVR’s Online Symposium on Healthcare Valuation

For most, the concept of a valuation multiple is easy for market participants to understand. Unfortunately, this simplicity of concept leads to widespread misapplication of valuation multiples and often results in sellers having unreasonable expectations. In the myth of the multiple, healthcare valuation expert Jason Ruchaber, CFA, ASA, will separate fact from fiction and explore the real financial and compliance considerations that drive FMV and purchase price in healthcare transactions.

2021 BVR – Myth of the Multiple



Our Founder shares his thoughts on navigating FMV compliance in the highly fluid and uncertain circumstances related to COVID-19.

by Jason Ruchaber, CFA, ASA


In this episode of AHLA’s monthly series on fraud and abuse issues, Matthew Wetzel, Associate General Counsel, Compliance Officer, GRAIL, and Stephen Bucci, Director, Berkeley Research Group (BRG) discuss with Jason Ruchaber, Founder and Managing Partner, Root Valuation, the impact that the coronavirus pandemic is having on fair market value. The podcast covers timely and important topics such as what sectors, if any, have seen a positive valuation impact from the crisis, how compensation arrangements can address this type of disruption, and how to deal with at-risk pay for clinicians.